Mutation and cell state compatibility is required and targetable in Ph + acute lymphoblastic leukemia minimal residual disease.
Peter S WinterMichelle L RamseierAndrew W NaviaSachit D SaksenaHaley StroufNezha SenhajiAlan DenAdelMahnoor MirzaHyun Hwan AnLaura BilalPeter DennisCatharine S LeahyKay ShigemoriJennyfer Galves-ReyesYe ZhangFoster PowersNolawit MulugetaAlejandro J GuptaNicholas L CalistriAlexandria Van ScoykKristen JonesHuiyun LiuKristen E StevensonSiyang RenMarlise R LuskinCharles P CouturierAva P SoleimanySrivatsan RaghavanRobert J KimmerlingMark M StevensLorin CrawfordDavid M WeinstockScott R ManalisAlex K ShalekMark A MurakamiPublished in: bioRxiv : the preprint server for biology (2024)
Relapse after remission on TKI can harbor mutations in ABL1, RAS, or neitherMutations and development-like cell state dictate fitness in residual diseaseCo-targeting cell state and ABL1 markedly reduces MRDBiophysical measurements provide an integrative, rapid measurement of cell state.